Featuring an interview with Prof Peter Schmid, including the following topics:

• Response to immunotherapy in breast cancer subtypes (0:00)
• Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51)
• Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03)
• ADC structure and treatment-related adverse events (19:02)
• Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06)
• Novel ADCs and bispecific antibodies under investigation for mBC (28:30)
• Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01)
• Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06)

CME information and select publications

Featuring a slide presentation and related discussion from Prof Peter Schmid, including the following topics:

• Evolution of the therapeutic landscape for metastatic triple-negative breast cancer; age of immunotherapy (0:00)
• Case: A woman in her early 40s with no actionable mutations (7:29)
• Evolution of antibody-drug conjugates (ADCs) in the management of metastatic breast cancer (11:13)
• TROP2-directed ADCs (15:22)
• Case: A woman in her early 50s with PD-L1-negative, HR-negative, HER2-low de novo metastatic breast cancer (20:21)
• Novel strategies utilizing approved and investigational ADCs (23:28)
• Case: A woman in her early 60s with loss of HER2 expression on disease progression (31:39)
• ADCs in combination with immunotherapy (32:51)

CME information and select publications

Featuring an interview with Dr Jonathan Strosberg, including the following topics:

• Overview of extrapulmonary neuroendocrine carcinoma (NEC) (0:00)
• Treatment strategies for extrapulmonary NEC (10:26)
• Targeting DLL3 in extrapulmonary NEC (18:49)
• Early clinical data with obrixtamig for extrapulmonary NEC (21:56)
• Additional investigational agents for extrapulmonary NEC (25:44)
• Case: A woman in her mid 50s with poorly differentiated metastatic NEC of unknown primary (27:20)
• Case: A man in his early 60s with poorly differentiated metastatic esophageal NEC (32:30)
• Clinical management of well-differentiated NEC (36:58)

CME information and select publications